Zhejiang University

Running trials

• Not yet recruiting

  Multicenter Prospective Validation of AI Models for Malignancy Risk Prediction in Pulmonary Nodules

  NCT07727122· Guangdong Provincial People's Hospital· Source

• Recruiting

  A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

  NCT05837052· Phase 2· Zhejiang University· Source

• Active, not recruiting

  Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

  NCT04624204· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

  NCT04380636· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  The Jiaxing Birth Cohort in China

  NCT03217656· Zhejiang University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure1 recruiting
• Lung cancer1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  The Dual Impact of Cirrhosis on Transplantation for Hepatocellular Carcinoma：a Two-center Retrospective Cohort Study in China

  NCT06420791· Xiao Xu· Source

• Completed

  Stratification for F-L Therapy After LT

  NCT06564103· Xiao Xu· Source

• Completed

  Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis

  NCT05205603· Phase 4· Sixth Affiliated Hospital, Sun Yat-sen University· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

  NCT04934722· Phase 3· Merck Sharp & Dohme LLC· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer427 works · 2 trials
• Stroke415 works · 0 trials
• Lung cancer355 works · 3 trials
• Obesity270 works · 1 trial
• Colorectal cancer262 works · 0 trials
• Alzheimer disease212 works · 0 trials
• Parkinson disease171 works · 0 trials
• Heart failure169 works · 0 trials
• Type 2 diabetes148 works · 0 trials
• Gastric and oesophageal cancer137 works · 0 trials
• Osteoarthritis123 works · 0 trials
• Asthma100 works · 0 trials
• Pancreatic cancer99 works · 0 trials
• Ovarian cancer97 works · 0 trials
• Chronic kidney disease95 works · 0 trials
• Crohn's disease95 works · 0 trials
• Depression94 works · 0 trials
• Atrial fibrillation93 works · 0 trials
• Epilepsy89 works · 0 trials
• Osteoporosis86 works · 0 trials
• Prostate cancer86 works · 1 trial
• Ulcerative colitis82 works · 1 trial
• Fatty liver disease (MASLD/MASH)79 works · 0 trials
• Psoriasis69 works · 0 trials
• Cervical cancer68 works · 0 trials
• Schizophrenia66 works · 0 trials
• COPD66 works · 0 trials
• HIV65 works · 0 trials
• Glioblastoma64 works · 0 trials
• Kidney cancer61 works · 0 trials